JANXJanux Therapeutics, Inc.
Price
-24%1YEnd-of-day closes, not the intraday tick.
Mostly good, one thing to check: safety
Quality mixed, a flag to check, growing in the filings, the market with it.
Charts
As reported to the SEC, without any scoring.
Janux Therapeutics, Inc. (JANX) reported revenue of $10M in Q2 2026 (quarter ended Jun 30, 2026). That came with net loss of $22M. For the full year FY2025, revenue was $10M (−5.6% year on year) and net income −$114M. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 6, 2026Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights.Earnings release · press release
- Jun 23, 2026On June 23, 2026, William Go, M.D., Ph.D. departed as Chief Medical Officer of Janux Therapeutics, Inc. (the "Company") under circumstances that the Company determined to constitute a termination without “Cause” under the terms of the Company’s Change in Control and Severance Benefit Plan (a copy of which is filed as …Other event · Form 8-K
- May 7, 2026Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.